Top

Published in:

01-07-2012 | Research

Association of GSTM1, GSTT1, GSTP1 and CYP2E1 Single Nucleotide Polymorphisms with Colorectal Cancer in Iran

Authors: Saeideh Ebrahimkhani, Ali Mohammad Asgharian, Babak Nourinaier, Khadijeh Ebrahimkhani, Nasrin Vali, Fatemeh Abbasi, Mohammad Reza Zali

Published in: Pathology & Oncology Research | Issue 3/2012

Abstract

Colorectal cancer is a major cause of morbidity and mortality both globally and in Iran. The aim of this study was to determine the association between genetic polymorphisms of glutathione S-transferases P1, M1 and T1 (GSTP1, M1, T1) and susceptibility to colorectal cancer (CRC). Genotyping of GSTP1, GSTM1 and GSTT1 was performed by the use of pyrosequencing. One hundred cases and healthy controls were enrolled into this study. Mean GSTT1 polymorphism type was significantly (P < 0.01) higher in cases as compared to controls (P < 0.0001: OR, 2.43: 95% CI, 1.47-4). On the other hand there is no significant association between GSTM1, GSTP1 and colorectal cancer. GSTs measurement may be useful as a colorectal marker in colorectal cancer and biopsies obtained at colonoscopy can be used to measure tumor markers.

Guengerich FP (1992) Metabolic activation of carcinogens. Pharmacol Ther 54:17–61PubMedCrossRef

Guengerich FP, Shimada T (1991) Oxidation of toxic and carcinogenic chemicals by human cytochrome P- 450 enzymes. Chem Res Toxicol 4:391–407PubMedCrossRef

Doll R, Peto R (1981) The causes of cancers: quantitative estimates of avoidable risks of cancers in the United States today. J Natl Cancer Inst 66(6):1191–1308PubMed

Chasseaud LF (1979) The role of glutathione and glutathione S_transferases in the metabolism of chemical carcinogens and other electrophiles agents. Adv Cancer Res 29:175–274PubMedCrossRef

Coles B, Ketterer B (1990) The role of glutathione transferases in chemical carcinogenesis. Crit Rev Biochem MolBiol 25:47–70CrossRef

Mucci LA, Wedren S, Tamimi RM, Trichopoulos D, Adami HO (2001) The role of gene-environment interaction in the aetiology of human cancer: examples from cancers of the large bowel, lung and breast. J Intern Med 249:477–493PubMedCrossRef

Kihara M, Kihara M, Noda K (1995) Risk of smoking for squamous and small cell carcinomas of the lung modulated by combinations of CYP1A1 and GSTM1 gene polymorphisms in a Japanese population. Carcinogenesis 16:2331–2336PubMedCrossRef

Lin DX, Tang YM, Peng Q, Lu SH, Ambrosone CB, Kadlubar FF (1998) Susceptibility to esophageal cancer and genetic polymorphisms in glutathione s- transferases T1, P1, and M1 and cytochrome P450 2E1. Cancer Epidemiology, Biomarker & Prey 7:1013–1018

Nebert DW, McKinnon RA, Puga A (1996) Human drug- metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol 15:273–280PubMedCrossRef

10.

Cheng KK, Day NE, Duffy SW, Lam TH, Fok M, Wong J (1992) Pickled vegetables in the aetiology of esophageal cancer in Hong Kong Chinese. Lancet 339:1314–1318PubMedCrossRef

11.

Hecht SS (1998) Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chem Res Toxicol 11(6):559–603PubMedCrossRef

12.

Guengerich FP, Kim DH, Iwasaki M (1991) Role of human cytochrome P-450IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 4:168–179PubMedCrossRef

13.

Gunter MJ, Watson MA, Loktionov AS et al (2005) No association between cytochrome P450 and glutathione S-transferase gene polymorphisms and risk of colorectal adenoma: results from the UK flexible sigmoidoscopy screening trial. Canc Epidemiol Biomarkers Prev 14(4):1028–30CrossRef

14.

Nakajima T, Wang R-S, Nimura Y et al (1996) Expression of cytochrome P450s and glutathione S- transferases in human esophagus with squamous- cell carcinomas. Carcinogenesis 17:1477–1481PubMedCrossRef

15.

Boyer TD, Kenney WC (1985) Preparation, characterization and properties of glutathione S-transferases. In: Zakim D, Vessey D (eds) Biochemical pharmacology and toxicology. Wiley, New York

16.

Mannervik B, Awasthi YC, Board PG et al (1992) Nomenclature for human glutathione S-transferases. Biochem J 282:305–306PubMed

17.

Meyer DJ, Coles B, Pemble SE, Gilmore KS, Fraser GM, Ketterer B (1991) θ, a new class of glutathione transferases purified from rat and man. Biochem J 274:409–414PubMed

18.

Lin D, Meyer DJ, Ketterer B, Lang NP, Kadlubar FF (1994) Effects of human and rat glutathione S-transferases on the covalent bonding of the N-acetoxy derivatives of heterocyclic amine carcinogens in vitro: a possible mechanism of organ specificity in their carcinogenesis. Cancer Res 54:4920–4926PubMed

19.

Pemble S, Schroeder KR, Spenser SR et al (1994) Human glutathione S-transferase (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J 300:271–276PubMed

20.

Evans WE, Relling MV (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286:487–91PubMedCrossRef

21.

Rebbeck TR (1997) Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomark Prev 6:733–743

22.

Strange RC, Lear JT, Fryer AA (1998) Glutathione S-transferase polymorphisms: influence on susceptibility to cancer. Chem Biol Interact 24(111–112):351–364CrossRef

23.

Nomania H, Mohammadzadeh Ghobadloob S, Yaghmaeib B, Rezvaniea NA, Yaghmaeic K (2005) Glutathione S-transferases activity in patients with colorectal cancer. Clin Biochem 38:621–624CrossRef

24.

Rajagopal R, Deakin M, Fawole AS et al (2005) Glutathione S- transferase T1 polymorphisms are associated with outcome in colorectal cancer. Carcinogenesis 26(12):2157–2163PubMedCrossRef

25.

Srivastava SK, Singhal SS, Hu X, Awasthi YC, Zimniak P, Singh SV (1999) Differential catalytic efficiency of allelic variants of human glutathione S-transferase Pi in catalyzing the glutathione conjugation of thiotepa. Arch Biochem Biophys 366:89–94PubMedCrossRef

26.

Houlston RS (1999) Glutathione S-transferase M1 status and lung cancer risk: a meta-analysis. Cancer Epidemiol Biomark Prev 8:675–682

27.

Baily R, Roodi N, Verrier CS, Yee CJ, Dupont WD, Parl F (1998) Breast cancer and CYP1A1, GSTM1, and GSTT1 polymorphisms: evidence of a lack of association in Caucasians and African Americans. Cancer Res 58:65–70

28.

Saadat I, Saadat M (2001) Glutathione S-transferase M1 and T1 null genotypes and the risk of gastric and colorectal cancers. Cancer Letters 169:21–26PubMedCrossRef

29.

de Jong M, Nolte IM, te Meerman GJ et al (2002) Low-penetrance genes and their involvement in colorectal cancer susceptibility. Cancer Epidemiol Biomarkers Prev 11:1332–52PubMed

30.

Board PG (1981) Gene deletion and partial deficiency of the glutathione S-transferase (ligandin) system in man. FEBS Lett 135:12–14PubMedCrossRef

31.

Pemble S, Schroeder KR, Spencer SS, Meyer DJ, Hallier E, Bolt HM (1994) Human glutathione S-transferase (GSTT1): cDNA cloning and the characterisation of a genetic polymorphism. Biochem J 300:271–276PubMed

32.

Ali-Osman F, Akande O, Antoun G, Mao JX, Buolamwini J (1997) Molecular cloning, characterisation and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase π variants. Evidence for differential catalytic activity of the encoded proteins. J Biol Chem 272:10004–11112PubMedCrossRef

33.

Casson AG, Zheng Z, Chiasson D et al (2003) Associations between genetic polymorphisms of Phase I and II metabolizing enzymes, p53 and susceptibility to esophageal adenocarcinoma. Cancer Detect Prev 27:139–146PubMedCrossRef

34.

Tan W, Song N, Wang GQ et al (2000) Impact of genetic polymorphisms in cytochrome P450 2E1 and glutathione S-transferases M1, T1, and P1 on susceptibility to esophageal cancer among high-risk individuals in China. Cancer Epidemiology Biomarkers Prev 9:551–556

35.

Butler WJ, Ryan P, Roberts-Thomson IC (2001) Metabolic genotypes and risk for colorectal cancer. J Gastroenterology Hepatol 16:631–635CrossRef

36.

Lu X M, Zang YM, Lin RY et al (2005) Relationship between genetic polymorphisms of metabolizing enzymes CYP2E1, GSTM1 and Kazakh’s esophageal squamous cell cancer in Xinjiang, China. World J Gastroenterol 28: 11(24): 3651-3654.

37.

Xing D, Tan W, Song N, Lin D (2000) Genetic polymorphism in hOGG1and susceptibility to esophageal cancer in Chinese. Zhonghuayixue Yichuanxue Zazhi 17:377–380

38.

Tan W, Chen GF, Xing DY, Song CY, Kadlubar FF, Lin DX (2001) Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population. Int J Cancer 95:96–101PubMedCrossRef

39.

40.

Dong CH, Yu SZ, Chen GC, Zhao DM, Hu Y (1998) Association of polymorphisms of glutathioneS transferase M1 and T1 genotypes with elevated aflatoxin and increased risk of primary liver cancer. Shijie Huaren Xiaohua Zazhi 6:463–466

41.

Thong S, Wyllie AH, Barnes D, Wolf CR, Spurr NK (1993) Relationship between the GSTMI genetic polymorphism and susceptibility to bladder, breast and colon cancer. Carcinogenesis 14:1821–1824CrossRef

42.

Chevenix-Trench G, Young J, Coggan M, Board P (1995) Glutathione S-transferase Ml, and Tl polymorphisms: susceptibility to colon cancer and age of onset. Carcinogenesis 16:1655–1657CrossRef

43.

Katoh T, Nagata N, Kuroda Y et al (1996) Glutathione S-transferase MI (GSTM1), and Tl(GSTT1) genetic polymorphism and susceptibility to gastric and colorectal adenocarcinoma. Carcinogenesis 17:1855–1859PubMedCrossRef

44.

Deakin M, Elder J, Hendrickse C et al (1996) Glutathione S-transferase GSTI’l genotypes and susceptibility to cancer: studies of interactions with GSTM1 in lung, oral, gastric and colorectal cancers. Carcinogenesis 17:881–884PubMedCrossRef

Title: Association of GSTM1, GSTT1, GSTP1 and CYP2E1 Single Nucleotide Polymorphisms with Colorectal Cancer in Iran
Authors: Saeideh Ebrahimkhani
Ali Mohammad Asgharian
Babak Nourinaier
Khadijeh Ebrahimkhani
Nasrin Vali
Fatemeh Abbasi
Mohammad Reza Zali
Publication date: 01-07-2012
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 3/2012
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-011-9490-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2012

A Proposed New Technique in Prostate Cancer Tissue Bio-Banking: Our Experience with a New Protocol

Mass Spectrometry-Based Salivary Proteomics for the Discovery of Head and Neck Squamous Cell Carcinoma

The Albumin and Monoclonal Protein Ratio as Prognostic Marker for Multiple Myeloma in the Era of Novel Agents

Overexpression of PTGIS Could Predict Liver Metastasis and is Correlated with Poor Prognosis in Colon Cancer Patients

SAHA Inhibits the Growth of Colon Tumors by Decreasing Histone Deacetylase and the Expression of Cyclin D1 and Survivin

Improving the Reproducibility of the Gleason Scores in Small Foci of Prostate Cancer - Suggestion of Diagnostic Criteria for Glandular Fusion

Keynote webinar | Spotlight on antibody–drug conjugates in cancer